171 related articles for article (PubMed ID: 38669609)
1. Curing Stage IV Melanoma: Where Have We Been and Where Are We?
Chan PY; Corrie PG
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438654. PubMed ID: 38669609
[TBL] [Abstract][Full Text] [Related]
2. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
Olszanski AJ
J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
[TBL] [Abstract][Full Text] [Related]
3. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
Chang W; Lee SJ; Park S; Choi MK; Hong JY; Kim YS; Maeng CH; Jung HA; Kim S; Lee J
Melanoma Res; 2013 Apr; 23(2):147-51. PubMed ID: 23411477
[TBL] [Abstract][Full Text] [Related]
4. Management of primary cutaneous and metastatic melanoma.
Rubin KM
Semin Oncol Nurs; 2013 Aug; 29(3):195-205. PubMed ID: 23958217
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
7. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapies in the treatment of stage II and III malignant melanoma.
Kavanagh D; Hill AD; Djikstra B; Kennelly R; McDermott EM; O'Higgins NJ
Surgeon; 2005 Aug; 3(4):245-56. PubMed ID: 16121769
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of melanomas].
Zimmer L; Vaubel J; Schadendorf D
Hautarzt; 2012 Dec; 63(12):952-8. PubMed ID: 23097082
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous melanoma: available therapy for metastatic disease.
Tarhini AA; Agarwala SS
Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of medical treatment in melanoma: current status and future prospects.
Garbe C; Eigentler TK; Keilholz U; Hauschild A; Kirkwood JM
Oncologist; 2011; 16(1):5-24. PubMed ID: 21212434
[TBL] [Abstract][Full Text] [Related]
12. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract][Full Text] [Related]
13. [Melanoma update].
Longvert C; Saiag P
Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Minutilli E; Feliciani C
Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
[TBL] [Abstract][Full Text] [Related]
15. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
Shah DJ; Dronca RS
Mayo Clin Proc; 2014 Apr; 89(4):504-19. PubMed ID: 24684873
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
17. Considering adjuvant therapy for stage II melanoma.
Poklepovic AS; Luke JJ
Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
[TBL] [Abstract][Full Text] [Related]
18. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics, diagnosis and treatment of melanoma in Serbia--the Melanoma Focus Study.
Kandolf-Sekulović L; Babović N; Jokić N; Nikolin B; Nikolić D; Janjić Z; Mijugković Z; Rajović M; Novaković M; Pejcić I; Kovaević P; Mihajlović D; Roganović T; Ferenc V; Nikolić J; Marinković M; Bizetić Z
Vojnosanit Pregl; 2015 Apr; 72(4):312-6. PubMed ID: 26040176
[TBL] [Abstract][Full Text] [Related]
20. Medical management of melanoma.
Brown CK; Kirkwood JM
Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
